ArticleFuture oncology (London, England)2024
The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring
Open access · hybridAbstract readClinical Trial Protocol
In one paragraph
Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
11.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 39 citations in OpenAlex.
- Efficacy of Zenocutuzumab inThe New England journal of medicine · 2025Trial
- HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).International journal of molecular sciences · 2026Review
- The evolving global landscape of first-in-class oncology drug innovation.Signal transduction and targeted therapy · 2026Review
- Structure, mechanism and clinical relevance of NRG1 fusions in cancer.Journal of biomedical science · 2026Review
- Roles of Her3 in carcinogenesis and advances in Her3-targeted cancer therapy.Discover oncology · 2026Review
- Analysis of clinical and genomic features in a Chinese cohort withTranslational lung cancer research · 2026Article
- Recent advances in molecular classification and multimodal treatment of intrahepatic cholangiocarcinoma.World journal of surgical oncology · 2026Review
- Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.European journal of medical research · 2026Article
- Monoclonal Antibodies and Derivatives: Therapeutic Tools for Cancer.Oncology research · 2026Review
- CCR-CCL axes as key upstream influencers of pancreatic ductal adenocarcinoma: CCR2-CCL2, CCR5-CCL5, CCR4-CCL17/22, CCR6-CCL20, CCR7-CCL19/21.Frontiers in immunology · 2026Review
- Mechanism of Bispecific Antibodies and Clinical Research Advances in Lung Cancer.Current cancer drug targets · 2026Review
- Antibodies to watch in 2025.mAbs · 2025Review
- Pancreatic cancer in 2025: Have we found a solution?World journal of gastroenterology · 2025Review
- Emerging therapeutic advancements in pancreatic cancer: a contemporary review.Discover oncology · 2025Review
- Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions.Cancers · 2025Review
- Bispecific antibodies: unleashing a new era in oncology treatment.Molecular cancer · 2025Review
- Bispecific Antibodies in Solid Tumors: Advances and Challenges.International journal of molecular sciences · 2025Review
- Development and application of a whole transcriptome sequencing assay for the detection of gene fusions in clinical cancer specimens.BMC cancer · 2025Article
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 7 countries.
Dong-Wan KimDepartment of Internal Medicine, Seoul National University College of Medicine & Seoul National University Hospital, Seoul, 03080, Republic of Korea.ORCID 0000-0001-5124-7132
Alison M SchramDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Antoine HollebecqueDrug Development (DITEP), GI Oncology, Gustave Roussy Cancer Campus, Villejuif, 94805, France.
Kazumi NishinoDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka, 540-0008, Japan.
Teresa MacarullaGastrointestinal and Endocrine Tumor Unit, Vall d´Hebrón University Hospital, Vall d´Hebrón Institute of Oncology (VHIO), Barcelona, 08035, Spain.
Sun Young RhaDepartment of Internal Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, 03722, Republic of Korea.
Michaël DuruisseauxDepartment of Respiratory Medicine and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, 69500, France.
Stephen V LiuThoracic Oncology and Developmental Therapeutics, Lombardi Comprehensive Cancer Center, Georgetown University, WA 20007, USA.
Mohammed Najeeb Al HallakDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Kumiko UmemotoDepartment of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan.
Claas WesselerDepartment of Pulmonology, Asklepios Tumorzentrum Hamburg, Klinikum Harburg, Hamburg, 21075, Germany.
James M ClearyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Christoph SpringfeldDepartment of Medical Oncology, Heidelberg University Hospital, Department of Medical Oncology, Heidelberg, 69120, Germany.
Cindy NeuzilletGI Oncology, Medical Oncology Department, Curie Institute, Versailles-Saint Quentin University, Saint-Cloud, 92064, France.
Andrew JoeClinical Development, Merus NV, Utrecht, 3584, The Netherlands.
Shekeab JauhariClinical Development, Merus NV, Utrecht, 3584, The Netherlands.
Jim FordClinical Trials, Merus NV, Utrecht, 3584, The Netherlands.
Koichi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
Merus (Netherlands) · NLAsklepios Klinikum Harburg · DEGeorgetown University · USHarvard University · USHeidelberg University · DEInstitut Gustave Roussy · FRMemorial Sloan Kettering Cancer Center · USNational Cancer Center Hospital East · JPOsaka International Cancer Institute · JPSeoul National University Hospital · KRSt. Marianna University School of Medicine · JPUniversité Claude Bernard Lyon 1 · FRVall d'Hebron Hospital Universitari · ESWayne State University · USYonsei University Health System · KR
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MMerus NVMerus NVNCI NIH HHS P30 CA008748
Abstract
Neuregulin 1 (
Indexed as
Carcinoma, Non-Small-Cell LungNeuregulin-1AdultAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarcinoma, Pancreatic DuctalClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicErb-b2 Receptor Tyrosine KinasesFemaleHumansLung NeoplasmsMaleMiddle AgedMulticenter Studies as TopicNeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesNeuregulin-1NRG1 protein, humanOncogene Proteins, FusionReceptor, ErbB-3eNRGy trialHER2HER3NRG1+NRG1 fusionNSCLCPDACrecruitingZenoZenocutuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.